Kezar Life Sciences Files 8-K for Material Agreement

TL;DR

Kezar Life Sciences signed a big deal, details in new 8-K filing.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on March 30, 2026, to report the entry into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This filing indicates a significant new contract or partnership for Kezar Life Sciences, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Kezar Life Sciences, Inc. (company) — Filer of the 8-K
• 0001645666 (company) — CIK number for Kezar Life Sciences, Inc.
• 2026-03-30 (date) — Filing date and period of report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share KZR The Nasdaq
• $6.955 — 001 per share (the " Shares "), for (i) $6.955 per Share, payable in cash, without int
• $50 m — he Merger Agreement) being no less than $50 million, and other customary closing cond
• $1,200,000 — on Fee ") of an amount in cash equal to $1,200,000. The Company Termination Fee is also pa
• $500,000 — rned prior to the Expiration Date: – $500,000 upon the first dosing of the first pati
• $5,000,000 — ndergo 24-hour in-unit monitoring; – $5,000,000 upon submission of a new drug applicati
• $12,500,000 — ug application ("NDA") to the FDA; – $12,500,000 upon NDA approval; – $20,000,000 if
• $20,000,000 — – $12,500,000 upon NDA approval; – $20,000,000 if Legacy Asset Net Sales (as defined i
• $500,000,000 — Agreement) are equal to or greaterthan $500,000,000 in any calendar year; – $50,000,000
• $50,000,000 — $500,000,000 in any calendar year; – $50,000,000 if Legacy Asset Net Sales are equal to
• $1,000,000,000 — Net Sales are equal to or greater than $1,000,000,000 in any calendar year; and – royalty

Filing Documents

• d106892d8k.htm (8-K) — 81KB
• d106892dex21.htm (EX-2.1) — 692KB
• d106892dex41.htm (EX-4.1) — 22KB
• d106892dex101.htm (EX-10.1) — 54KB
• d106892dex991.htm (EX-99.1) — 19KB
• g106892g0330085400132.jpg (GRAPHIC) — 5KB
• g106892g0330085400388.jpg (GRAPHIC) — 7KB
• 0001193125-26-130486.txt ( ) — 1252KB
• kzr-20260330.xsd (EX-101.SCH) — 4KB
• kzr-20260330_def.xml (EX-101.DEF) — 13KB
• kzr-20260330_lab.xml (EX-101.LAB) — 22KB
• kzr-20260330_pre.xml (EX-101.PRE) — 14KB
• d106892d8k_htm.xml (XML) — 5KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits Exhibit Number Description 2.1* Agreement and Plan of Merger, dated as of March 30, 2026, by and among Kezar Life Sciences, Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc. and, solely for purposes of Section 10.13, Aurinia Pharmaceuticals Inc. 4.1 Amendment No. 3, dated as of March 30, 2026, to the Rights Agreement, dated as of October 17, 2024, by and between Kezar Life Sciences, Inc. and Computershare Trust Company, N.A., as rights agent. 10.1 Form of Tender and Support Agreement, dated as of March 30, 2026, by and among Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Kezar Life Sciences, Inc. and the stockholders party thereto. 99.1 Joint press release issued by Aurinia Pharmaceuticals Inc. and Kezar Life Sciences, Inc., dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain annexes, exhibits and schedules have been omitted pursuant to Item 601(a)(5) or Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. 5 Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements related to the Buyer Entities and Kezar and the acquisition by the Buyer Entities of Kezar, including express or implied forward-looking statements about the future operations and performance of Kezar and Parent. These forward-looking statements are within the meaning of U.S. federal securities laws, including, without limitation, statements regarding the anticipated timing of and closing of the Merger, the proposed merger and related transactions contemplated by the Merger Agreement (collectively referred to as the "transactions"). The words "anticipate," "a

View Full Filing

View this 8-K filing on SEC EDGAR